Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sickle cell clues to diabetes risk hidden in DNA

NCT ID NCT02922296

NEW Knowledge-focused Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at the University of Illinois at Chicago are studying how the bodies of adults with sickle cell disease handle glucose, cholesterol, and triglycerides, and why some of them develop diabetes. The study enrolls 75 adults over 35 with major sickle cell genotypes. Participants give blood samples so scientists can examine DNA for genes linked to diabetes and high cholesterol, and RNA to see how those genes are active. The goal is to understand the biology well enough to guide future treatments that control blood sugar and prevent diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers identify genes that protect against or cause diabetes in sickle cell disease, this could point toward new ways to prevent or control high blood sugar in these patients.
What could go wrong
This is an observational study with no treatment, so it cannot prove that any gene or metabolic factor causes diabetes. Findings from 75 adults may not apply to children, other genotypes, or people without sickle cell disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2015

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult sickle cell disease subjects, with or without diabetes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major sickling genotype (hemoglobin SS, Sbeta0-thalassemia, SOarab, SDpunjab) * Age \>35 years * BMI \<25 kg/m2 or \>26 kg/m2 * Steady state, defined as \>two weeks from a hospitalization for vaso-occlusive crisis, infection or surgery and not requiring immediate parenteral medication for pain control * Fasting state (\>8 hours since ingesting food or medication for diabetes) Exclusion Criteria: * Patients receiving insulin therapy * Acute inflammatory or infectious illness or injury

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus Sickle cell disease

Contacts and locations

Locations

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.